Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
all-trans retinoic acid + tamoxifen
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy consisting of all-trans retinoic acid (ATRA) and tamoxifen. ATRA is a derivative of vitamin A that acts primarily as an agonist for retinoic acid receptors, promoting cell differentiation and apoptosis. Tamoxifen is a selective estrogen receptor modulator (SERM) that antagonizes estrogen receptor alpha (ERα), inhibiting estrogen-driven tumor growth. The combination has been studied for its additive or synergistic antitumor effects in several cancers, including ERα-positive ovarian cancer, advanced breast cancer, and acute promyelocytic leukemia (APL). Mechanistically, ATRA can inhibit genes related to the ERα signaling pathway and enhance sensitivity to tamoxifen in ERα-positive tumors[1][2][3]. In leukemia models, tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of ATRA[4]. This combination aims to overcome resistance mechanisms seen with single-agent therapy.
- Other names
- ATRA + tamoxifenall-trans-retinoic acid and tamoxifen
02
Targets
RARA (Retinoic acid receptor alpha)ESR1 (ERα)PIN1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1)
Beyond the preview
Go deeper on all-trans retinoic acid + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on all-trans retinoic acid + tamoxifen.